Advertisement

Topics

Landauer, Inc. Reports Fiscal 2017 Third Quarter Results - Earnings Per Diluted Share Of $0.66

12:09 EDT 8 Aug 2017 | PR Newswire

GLENWOOD, Ill., Aug. 8, 2017 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring and outsourced medical physics services, today reported financial results for its fiscal 2017 third quarter ended June 30, 2017.

Fiscal 2017 Third Quarter Highlights

  • Reported revenue of $39.9 million compared to $37.9 million in the third quarter of 2016 
    • Excluding the divested Medical Products business, pro forma revenue increased 7.5% compared to the prior year
    • Military revenues increased $0.7 million
  • Reported net income of $6.4 million compared to $7.3 million in the third quarter of 2016
    • Prior year net income included a $1.7 million post-tax gain on divestiture of the Medical Products business
  • On a GAAP basis, earnings per diluted share of $0.66 compared to $0.76 in the third quarter of 2016
  • Increasing full year 2017 outlook for diluted earnings per share to $1.81 to $1.87 from the previous range of $1.65 to $1.71

Mike Kaminski, President and Chief Executive Officer of Landauer stated, "Our third quarter results reflect the continued growth of our recurring business as well as the fulfillment of our non-recurring military order and a one-time tax benefit all contributing to a strong financial quarter. During the quarter we continued to advance our strategic initiatives in informatics and our Verifii digital dosimetry platform remains on schedule for a controlled commercial launch in the second half of calendar 2017."

Third Quarter Financial Overview

Revenues for the third fiscal quarter of 2017 were $39.9 million, a 5.3% increase compared to revenues of $37.9 million for the third fiscal quarter of 2016.  Excluding the Medical Products business which was divested in the third fiscal quarter of 2016, total revenues increased $2.8 million or 7.5% compared to the prior year period.  Radiation Measurement revenues for the quarter increased to $29.6 million from $27.5 million for the third fiscal quarter of 2016.  Military sales in the third fiscal quarter of 2017 increased $0.7 million compared to the prior year period.  The Company completed its final shipment for the National Guard order during the third fiscal quarter of 2017.  While the Company is continuing to pursue orders for its Radwatch products, there are currently no open contracts or purchase orders for military products.  Medical Physics revenues increased $0.7 million, or 7.3%, to $10.3 million.

Operating income for the third fiscal quarter of 2017 was $8.6 million, compared to operating income of $7.7 million for the third fiscal quarter of 2016.  Operating income increased $0.9 million compared to the prior year period due primarily to the timing of military sales.

Fiscal Nine Months Financial Overview

Revenues for the first nine months of fiscal 2017 were $116.6 million, a 3.6% increase compared to $112.5 million for the first nine months of fiscal 2016. Excluding the divested Medical Products business, total revenues increased $9.9 million or 9.3% compared to the prior year period.  Radiation Measurement revenues increased to $85.9 million from $77.7 million in the prior year period.  Military sales in the first nine months of fiscal 2017 increased $5.8 million compared to the prior year period. The Medical Physics segment increased $1.8 million, driven by demand for imaging services.

Operating income for the first nine months of fiscal 2017 was $23.8 million, compared to operating income of $21.2 million for the first nine months of fiscal 2016. Excluding the operating income from the divested Medical Products business, operating income increased $3.7 million compared to the prior year period due primarily to the timing of military sales.

Fiscal 2017 Outlook

Based on its results for the first nine months of 2017, the Company is increasing its full year 2017 outlook for diluted earnings per share to $1.81 to $1.87 from the previous range of $1.65 to $1.71. The Company continues to expect fiscal 2017 revenues in the range of $149 million to $154 million.

The revised earnings per share guidance reflects the Company's first three quarters of strong margins driven by the fulfillment of the episodic military orders and cost control.  The fourth quarter expectations are consistent with prior statements reflecting minimal capital shipments and an increase in non-recurring expenses associated with the Verifii launch and an increase in incentive accruals.

Use of Non-GAAP Financial Measures

Management believes the disclosure of certain non-GAAP financial measures enhances investor understanding of our financial performance.  Non-GAAP financial measures disclosed in this report include: EBITDA, Pro Forma Revenue and Pro Forma Operating Income.

EBITDA is presented here not as an alternative to net income, but rather as a measure of the Company's operating performance and is not intended to be a presentation in accordance with GAAP. Since EBITDA (generally, net income plus interest expenses, taxes, depreciation and amortization) is not calculated identically by all companies, this presentation may not be comparable to EBITDA presentations disclosed by other companies. Management believes that EBITDA is useful in evaluating the Company's operating performance compared to that of other companies in its industry because the calculation of EBITDA generally eliminates the effects of certain non-cash and other items that may vary for different companies for reasons unrelated to overall operating performance.

The Pro Forma Revenue and Pro Forma Operating Income measures exclude the Medical Products business, which was divested in May 2016. 

These financial measures are not recognized measurements under GAAP and should not be considered as an alternative to the most directly comparable measures presented in accordance with GAAP. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is included within this news release.

Conference Call Details

Landauer has scheduled its third quarter conference call for investors over the Internet on Tuesday, August 8, 2017, at 4:00 p.m. Central Time (5:00 p.m. Eastern Time). To participate, callers should dial 866-866-1542 (within the United States and Canada), or 707-294-1539 (international callers), passcode 63881527, about 10 minutes before the presentation. To listen to a webcast on the Internet, please go to the Company's website at http://www.landauer.com at least 15 minutes early to register, download and install any necessary audio software. Investors may access a replay of the call by dialing 855-859-2056 (within the United States and Canada), or 404-537-3406 (international callers), passcode 63881527, which will be available through Thursday, September 7, 2017. The replay will also be available on Landauer's website for 30 days following the call.

About Landauer

Landauer is a leading global provider of technical and analytical services to determine occupational and environmental radiation exposure, as well as the leading domestic provider of outsourced medical physics services. For more than 50 years, the Company has provided complete radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation poses a potential threat to employees. Landauer's services include the manufacture of various types of radiation detection monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings. The Company provides its dosimetry services to approximately 1.8 million individuals globally. In addition, through its Medical Physics segment, the Company provides therapeutic and imaging physics services to the medical physics community. For information about Landauer, please visit their website at http://www.landauer.com

Safe Harbor Statement

Some of the information shared here (including, in particular, the section titled "Fiscal 2017 Outlook") constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and uncertainties associated with the Company's future performance; the Company's development and introduction of new technologies in general; the ability to protect and utilize the Company's intellectual property; continued customer acceptance of the InLight technology; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats; military and other government funding for the purchase of certain of the Company's equipment and services; the impact on sales and pricing of certain customer group purchasing arrangements; changes in spending or reimbursement for medical products or services; the costs associated with the Company's research and business development efforts; the usefulness of older technologies and related licenses and intellectual property; the effectiveness of and costs associated with the Company's IT platform enhancements; the anticipated results of operations of the Company and its subsidiaries or joint ventures; valuation of the Company's long-lived assets or reporting units relative to future cash flows; changes in pricing of services and products; changes in postal and delivery practices; the Company's business plans; anticipated revenue and cost growth; the ability to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions, including instability in capital markets which could impact availability of short and long-term financing; the timing and extent of changes in interest rates; the level of borrowings; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the costs of obligations under the Company's benefit plans; and pending accounting pronouncements. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today. These risks and uncertainties also may result in changes to the Company's business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses. Additional information may be obtained by reviewing the information set forth in Item 1A. "Risk Factors" and Item 7A. "Quantitative and Qualitative Disclosures about Market Risk" and information contained in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2016 and other reports filed by the Company, from time to time, with the Securities and Exchange Commission. The Company does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in the Company's expectations, except as required by law.

Financial Tables Follow

Landauer, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in Thousands)

June 30,
2017

September 30,
2016

Assets

Cash and cash equivalents

$

21,064

$

13,285

Receivables, net of allowances of $1,324 at June 30, 2017 and $1,296 at
September 30, 2016

33,618

31,998

Inventories

5,229

5,670

Prepaid expenses and other current assets

13,348

5,049

Total current assets

73,259

56,002

Net property, plant and equipment

47,226

46,417

Equity in joint ventures

26,488

26,174

Goodwill

33,916

33,807

Intangible assets, net of accumulated amortization of $12,704 at June 30, 2017 and $11,772 at September 30, 2016

8,602

9,297

Other assets

8,675

19,119

Total assets

$

198,166

$

190,816

Liabilities

Total current liabilities

$

36,307

$

34,498

Long-term debt

100,600

109,100

Other non-current liabilities

30,374

26,619

Total liabilities

167,281

170,217

Stockholders' equity

Landauer, Inc. stockholders' equity

29,432

19,178

Noncontrolling interest

1,453

1,421

Total stockholders' equity

30,885

20,599

Total Liabilities and Stockholders' Equity

$

198,166

$

190,816


Landauer, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations (Unaudited)

Three Months Ended
June 30,

Nine Months Ended
June 30,

(Dollars in Thousands, Except per Share)

2017

2016

2017

2016

Total revenues

$

39,888

$

37,854

$

116,582

$

112,466

Cost and expenses:

Cost of sales

18,801

18,336

55,543

54,678

Selling, general and administrative

12,504

11,805

37,205

36,606

Total costs and expenses

31,305

30,141

92,748

91,284

Operating income

8,583

7,713

23,834

21,182

Equity in income of joint ventures

1,206

244

3,015

797

Other expense, net

(680)

2,847

(2,340)

728

Income before taxes

9,109

10,804

24,509

22,707

Income tax expense

2,509

3,382

7,976

7,074

Net income

6,600

7,422

16,533

15,633

Less:  Net income attributed to noncontrolling interest

200

157

557

446

Net income attributed to Landauer, Inc.

$

6,400

$

7,265

$

15,976

$

15,187

Net income per share attributable to Landauer, Inc. shareholders:

Basic

$

0.67

$

0.76

$

1.67

$

1.59

Weighted average basic shares outstanding

9,585

9,531

9,562

9,523

Diluted

$

0.66

$

0.76

$

1.66

$

1.58

Weighted average diluted shares outstanding

9,606

9,564

9,595

9,555


Landauer, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited)

Nine Months Ended
June 30,

(Dollars in Thousands)

2017

2016

Cash flows from operating activities:

Net income

$

16,533

$

15,633

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

8,047

8,461

Equity in income of joint ventures

(3,015)

(797)

Dividends from joint ventures

1,341

1,195

Stock-based compensation and related net tax benefits

2,449

2,048

Current and long-term deferred taxes, net

10,568

3,639

Gain on disposition of business

-

(3,904)

Gain on sale, disposal and abandonment of fixed assets

23

368

Gain on investments

(411)

(558)

Changes in operating assets and liabilities

(3,522)

(3,866)

Net cash provided by operating activities

32,013

22,219

Net cash (used in) provided by investing activities

(7,500)

3,795

Cash flows from financing activities:

Long-term borrowings, net

(8,500)

(21,085)

Dividends paid to stockholders

(7,979)

(7,933)

Other financing activities, net

(231)

(417)

Net cash used in financing activities

(16,710)

(29,435)

Effects of foreign currency translation

(24)

82

Net increase (decrease) in cash and cash equivalents

7,779

(3,339)

Opening balance - cash and cash equivalents

13,285

15,314

Ending balance - cash and cash equivalents

$

21,064

$

11,975

Non-GAAP Financial Measures

A reconciliation of EBITDA, Pro Forma Revenue and Pro Forma Operating Income (i.e., non-GAAP financial measures) to the most directly comparable GAAP measures is provided below:

Three Months Ended
June 30,

Nine Months Ended
June 30,

(Unaudited, Dollars in Thousands)

2017

2016

2017

2016

EBITDA

Net income attributed to Landauer, Inc.

$

6,400

$

7,265

$

15,976

$

15,187

Add back:

Net financing costs

580

589

1,752

2,420

Depreciation and amortization

2,695

2,800

8,047

8,461

Provision for income taxes

2,509

3,382

7,976

7,074

Earnings before interest, taxes, depreciation and
amortization (EBITDA)

$

12,184

$

14,036

$

33,751

$

33,142

Three Months Ended
June 30,

Nine Months Ended
June 30,

(Unaudited, Dollars in Thousands)

2017

2016

2017

2016

Pro Forma Revenue

Total Revenues, as reported

$

39,888

$

37,854

$

116,582

$

112,466

Less:

Medical Products adjustment

-

(800)

-

(5,802)

Total Revenues, pro forma

$

39,888

$

37,054

$

116,582

$

106,664

Three Months Ended
June 30,

Nine Months Ended
June 30,

(Unaudited, Dollars in Thousands)

2017

2016

2017

2016

Pro Forma Operating Income

Operating Income, as reported

$

8,583

$

7,713

$

23,834

$

21,182

Less:

Medical Products adjustment

-

(140)

-

(1,062)

Total Operating Income, pro forma

$

8,583

$

7,573

$

23,834

$

20,120

Segment Information

The following tables summarize financial information for each reportable segment for the three and nine months ended June 30:

Three Months Ended
June 30,

Nine Months Ended
June 30,

(Dollars in Thousands)

2017

2016

2017

2016

Revenues by segment:

Radiation Measurement

$

29,594

$

27,492

$

85,918

$

77,716

Medical Physics

10,294

9,562

30,664

28,948

Medical Products

-

800

-

5,802

Consolidated revenues

$

39,888

$

37,854

$

116,582

$

112,466

Three Months Ended
June 30,

Nine Months Ended
June 30,

(Dollars in Thousands)

2017

2016

2017

2016

Operating income (loss) by segment:

Radiation Measurement

$

12,138

$

10,294

$

34,779

$

29,161

Medical Physics

789

756

2,140

2,452

Medical Products

-

141

-

1,063

Corporate

(4,344)

(3,478)

(13,085)

(11,494)

Consolidated operating income

$

8,583

$

7,713

$

23,834

$

21,182

For Further Information Contact:
Michael DeGraff 
Sard Verbinnen & Co
Phone: 312.895.4734 
Email: mdegraff@sardverb.com 

View original content:http://www.prnewswire.com/news-releases/landauer-inc-reports-fiscal-2017-third-quarter-results--earnings-per-diluted-share-of-066-300501461.html

SOURCE Landauer, Inc.

NEXT ARTICLE

More From BioPortfolio on "Landauer, Inc. Reports Fiscal 2017 Third Quarter Results - Earnings Per Diluted Share Of $0.66"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...